Dexketoprofeno Qualigen

Quick links

Choose a section

Quick links to important sections

Advertisements

Dexketoprofeno Qualigen

Advertisements
Advertisements

Overview of Dexketoprofeno Qualigen

This section establishes the definitive identity, classification, and general purpose of the medicine, emphasizing its unique pharmaceutical features while strictly maintaining E-E-A-T principles and excluding details on usage, safety, or dosage.

Property Description
Active ingredient Dexketoprofen Trometamol
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Drug Differentiation Chiral switch S-enantiomer; highly water-soluble salt for rapid action.
Legal Status Prescription-only medicine (POM) in many regions (e.g., UK), though available OTC in others.
Origin Synthetic, propionic acid derivative

Defining Dexketoprofeno Qualigen: Classification and Composition

Dexketoprofeno Qualigen is a pharmaceutical product whose core component, Dexketoprofen, is classified as a Non-steroidal anti-inflammatory drug (NSAID) and functions as a non-opioid analgesic. The medicine is a prescription-only item in numerous countries, reflecting its medical oversight requirement. The active substance, Dexketoprofen, is formulated as the highly soluble Trometamol salt, a crucial feature designed to enhance absorption. Chemically, this compound is a synthetic derivative of propionic acid, representing the pure S-enantiomer, which is the specific isomer responsible for the desired therapeutic effect.

General Purpose and Core Physiological Action

The primary general purpose of Dexketoprofen is to provide effective systemic relief from discomfort associated with the body’s inflammatory responses. This indicates that the medicine effectively helps ease discomfort by quickly targeting the underlying processes that cause inflammation and pain. The mechanism involves the inhibition of cyclooxygenase (COX) enzymes, which limits the production of prostaglandins, the specific chemical mediators that transmit pain signals. This action establishes the drug as a powerful dual-action agent against both the sensation of pain and the visible signs of inflammation.

Available Forms and Pharmaceutical Type

Dexketoprofeno Qualigen is a single-ingredient product, offering clinical flexibility through multiple high-level pharmaceutical forms, including film-coated tablets, granules for oral solution, and an injectable solution for parenteral administration. This rapid-absorption formulation, specifically the highly water-soluble Trometamol salt, is a defining characteristic, often resulting in a quicker onset of analgesic action compared to the parent racemic compound. The rapid absorption is a key differentiating factor, making the medicine particularly suitable when prompt relief is required in acute situations, such as managing postoperative discomfort.

Advertisements

What side effects are possible with Dexketoprofeno Qualigen?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for Dexketoprofeno Qualigen, based on regulatory documentation. This information defines the medicine's risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they have been reported in studies and surveillance:

Classification Definition (Affected Users)
Common Affects 1 to 10 users in 100
Uncommon Affects 1 to 10 users in 1,000
Rare Affects 1 to 10 users in 10,000
Very Rare Affects less than 1 user in 10,000

Observed system-organ classes involved include gastrointestinal disorders, nervous system disorders, skin and subcutaneous tissue disorders, and cardiovascular disorders.


Serious Adverse Reactions and Safety Limitations

Serious adverse reactions formally documented include severe hypersensitivity (anaphylactic) reactions, potentially life-threatening gastrointestinal ulceration, haemorrhage, or perforation, serious skin reactions (e.g., Stevens-Johnson Syndrome), and acute renal failure. These events are generally classified as Rare or Very Rare.

Population-Specific and Exposure Restrictions:

  • Contraindications: The medicine is strictly contraindicated (prohibited) for patients with a known history of gastrointestinal bleeding or perforation related to previous NSAID use, active peptic ulceration, severe heart failure, severe renal or hepatic impairment, and known allergy to this substance or other NSAIDs.
  • Pregnancy Restriction: Use is specifically prohibited during the third trimester of pregnancy due to documented risk to the fetus.
  • Dose/Duration Pattern: Regulatory information notes that the risk of cardiovascular thrombotic events (like heart attack or stroke) may be slightly increased with high doses and prolonged treatment duration. The lowest effective dose for the shortest possible duration is emphasized to minimize documented risks.
Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Dexketoprofeno Qualigen

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Symptoms are typically limited, including nausea, vomiting, abdominal pain, dizziness, somnolence, headache, and disorientation as the most common manifestations.
Physiological Systems Affected Primary systems involved include the Gastrointestinal and Central Nervous System. Severe outcomes may also affect Renal and Hepatic function.
Dose-related or exposure-related factors Overdose risk is associated with ingestion of large quantities. The elderly have an increased frequency of severe adverse reactions, notably gastrointestinal bleeding.
Emergency-response statements Management requires symptomatic and supportive treatment; procedures such as gastric lavage and activated charcoal may be considered in a healthcare setting.
When immediate medical help is required Seek immediate medical attention for any suspected overdose; contact emergency services if severe symptoms develop.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Symptoms are generally reversible with supportive care; however, the potential for severe outcomes is documented (e.g., GI bleeding, acute renal failure, convulsions).
Regulatory basis Based on the Summary of Product Characteristics (SmPC) / Prescribing Information (FDA) for Dexketoprofen Trometamol.

Resulting Overdose Structure

Official overdose statements:

  • No specific antidote is known for Dexketoprofen Trometamol.
  • Severe outcomes include Gastrointestinal bleeding, acute renal failure, and the potential for convulsions.
  • Patients require close clinical observation and monitoring of vital signs and laboratory parameters.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by outlining the most common manifestations alongside the potential for life-threatening complications. Since no specific antidote is known, this profile mandates that any suspected overdose requires individuals to seek immediate medical attention for management involving supportive treatment, procedural options (where appropriate), and continuous clinical monitoring, ensuring rapid response to severe systemic effects.

Advertisements

Therapeutic Uses of Dexketoprofeno Qualigen

What Dexketoprofeno Qualigen Treats: Main Uses and Benefits

The primary therapeutic utility of this medicine is to provide symptomatic assistance for physical discomfort across several key domains, and it is commonly used for the temporary relief of such symptoms. This provides supportive symptomatic assistance in areas where short-term management is appropriate, and generally provides supportive relief to help ease the symptomatic load.

The medication is applicable in conditions characterized by symptoms that create noticeable physiological strain and is relevant for easing discomfort in contexts like managing acute pain from musculoskeletal injuries, supporting recovery after dental or minor surgical procedures, and addressing the cramping and pain associated with dysmenorrhoea. It is used for managing symptom clusters that may become disruptive, supporting patients during difficult episodes by easing distress during these periods.

“The medicine is commonly used across conditions presenting with acute episodes, supporting patients during episodes of increased discomfort or tension.”


Quick Fact: Relief for Acute Pain Dexketoprofeno Qualigen is generally applied when symptoms intensify and supportive relief is needed, particularly for acute pain symptoms that interfere with routine activities. It assists with maintaining functional stability during these phases.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use This Medicine

The eligibility for Dexketoprofeno Qualigen (Dexketoprofen Trometamol) is determined strictly by the patient’s age, pre-existing medical conditions, and physiological status, as defined in official regulatory labeling.

Absolute Contraindications (Must Not Use) Restricted Use/Exclusions (Conditional or Prohibited)
Severe Organ Dysfunction: Severe heart failure, moderate to severe renal dysfunction (creatinine clearance le 59 ml/min), or severe hepatic impairment. Age: Safety and efficacy are not established in children and adolescents; the product should not be used in those under 18 years of age.
Gastrointestinal Risk: Active peptic ulcer/gastrointestinal haemorrhage, history of GI bleeding related to previous NSAIDs, Crohn’s disease, or ulcerative colitis. Older Adults: Requires commencement of treatment at the lowest available dose due to increased vulnerability to adverse effects.
Allergy & Bleeding: Hypersensitivity to dexketoprofen or any other NSAID, history of NSAID-induced asthma/allergic reactions, or active bleeding disorders. Pregnancy/Lactation: Use is contraindicated during the third trimester of pregnancy and the lactation period (breastfeeding).

Individuals with mild to moderate hepatic impairment or mildly impaired renal function may use the medicine but must start therapy at a reduced daily dose and be closely monitored. The medicine is also contraindicated in patients with severe dehydration or those with known photoallergic reactions to ketoprofen or fibrates.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile for Dexketoprofeno Qualigen

Regulatory documentation mandates specific constraints for co-administration due to the risk of severe adverse outcomes arising from pharmacodynamic (PD) risk reinforcement and altered pharmacokinetic (PK) clearance.

Classification Interacting Medicines / Products
Combinations to Avoid Other NSAIDs (including COX-2 inhibitors), due to the officially documented additive risk of severe gastrointestinal (GI) toxicity and bleeding.
Not Recommended Anticoagulants (e.g., Warfarin, Heparins), due to the increased risk of severe bleeding and interference with haemostasis [SmPC].

Interactions Affecting GI and Renal Risk

Co-administration with agents such as Oral Corticosteroids, SSRIs, and Anti-platelet agents (including low-dose acetylsalicylic acid) carries an increased, officially documented risk of GI ulceration or bleeding. Similarly, co-use with Diuretics, ACE Inhibitors, and Nephrotoxic Agents (e.g., Ciclosporin, Tacrolimus) enhances the risk of renal toxicity [SmPC].

Effects on Drug Concentration

The medicine is officially documented to increase the plasma concentration of Probenecid and to decrease the elimination of Pemetrexed [Regulatory Information].

Administration Constraints

Consumption of Alcohol (Ethanol) is not recommended due to an officially documented increase in the risk of serious GI side effects. To prevent a delay in the absorption rate for acute pain management, administration should be separated from food, specifically at least 15 to 30 minutes before meals [SmPC].

Population Note

Elderly patients are noted in official labeling as having an increased susceptibility to interaction risks due to a higher frequency and severity of adverse reactions [SmPC].

Advertisements

Mechanism of Action

Inhibition of Prostaglandin Synthesis via Cyclooxygenase Enzymes

The mechanism of Dexketoprofeno Qualigen centers on the non-selective, competitive inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. The active S(+)-enantiomer prevents these enzymes from initiating the Arachidonic Acid cascade, thereby restricting the formation of prostaglandins and other prostanoids. This blockade of chemical mediator production leads directly to the modulation of inflammatory processes.

Influence on Nociceptive Signaling and Central Thermoregulation

By reducing the overall concentration of prostaglandins, particularly PGE2, the drug influences two distinct physiological systems. Peripherally, the reduced presence of PGE2 decreases the chemical sensitization of nociceptors, thereby increasing the activation threshold of nociceptors. Centrally, the lack of PGE2 synthesis in the hypothalamus reverses the fever-inducing signal, allowing the body's thermal set point to be restored to its non-febrile state.

Kinetics of COX Inhibition via Trometamol Salt

A characteristic kinetic feature is the formulation of Dexketoprofen as the highly soluble Trometamol salt. This formulation significantly accelerates the rate at which the active ingredient is absorbed into the systemic circulation. Rapid systemic uptake ensures that the concentration required to initiate competitive COX inhibition is achieved quickly, contributing to a swift initiation of the physiological effects resulting from the enzyme inhibition.

Advertisements

Dosage and Administration Information

How to Use Dexketoprofeno Qualigen

Dexketoprofeno Qualigen is administered through established routes: the oral route (using tablets or granules for solution) and the parenteral route (using an injectable solution). The parenteral form may be administered as a slow intramuscular (IM) injection or a slow intravenous (IV) bolus or infusion, according to the clinical setting.

Official Dosing and Administration Parameters

Feature Guideline
Oral Dosing Typically 12.5 mg every 4–6 hours or 25 mg every 8 hours. The total daily oral intake must not exceed 75 mg.
Parenteral Dosing 50 mg every 8–12 hours, with a minimum interval of six hours between administrations. The maximum total daily dose for the parenteral route is 150 mg.
Timing Oral forms are recommended to be taken 15 to 30 minutes before meals to optimize the rate of absorption and achieve a quicker response.
Duration The medicine is restricted to short-term use only. Parenteral use is specifically limited to two consecutive days, requiring a transition to the oral route as soon as feasible.
Dose Adjustments For older adults and patients with mild renal or mild to moderate hepatic impairment, the initial total daily dose is reduced to 50 mg.

The administration process includes specific requirements for preparation and handling. For instance, oral granules must be completely dissolved in water and ingested immediately. Procedural instructions for intravenous use specify that the bolus must be administered over no less than 15 seconds. Additionally, the solution prepared for infusion must be actively protected from natural daylight during the entire administration process. These instructions define the standardized approach for correct usage.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dexketoprofeno Qualigen


1. Evidence for Use in Acute Postoperative Pain

Dexketoprofeno has been studied to evaluate how symptoms change over time after surgical procedures. The clinical evaluation primarily relies on short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms of physical discomfort after common surgeries, such as dental extractions or minor orthopedic procedures. Researchers examined outcomes related to physical discomfort by measuring changes in patient-reported outcomes describing perceived discomfort using standardized pain scales.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations. These findings describe patterns observed when the drug was compared to a non-active treatment (placebo) or other studied treatments. Research highlights measured changes during the study period, including the timing of the first recorded change in symptoms and the overall difference in pain scores over defined time intervals, usually the first few hours after administration. Reports included data on the observed intake of opioid rescue medication in patients receiving Dexketoprofen compared to those in the study’s control groups.


2. Evidence for Use in Acute Musculoskeletal Pain and Primary Dysmenorrhoea

The research base includes Randomized Controlled Trials and other studies examining short-term symptom changes in conditions associated with acute or disruptive episodes, such as sudden back pain, minor injury pain, or pain associated with the menstrual cycle (primary dysmenorrhoea).

For musculoskeletal pain, studies evaluated adults presenting with pain associated with acute or irritative states, exploring patient-reported outcomes describing perceived discomfort and functional status. For dysmenorrhoea, trials focused on adult women, examining outcomes describing episodic changes, the timing of recorded symptomatic change, and pain intensity over the first few hours of the symptomatic phase.

Evidence for these indications is limited in that the follow-up durations were restricted, meaning the studies primarily reflect the management of the immediate symptomatic phase rather than long-term changes or chronic conditions.


3. Research Gaps and Follow-up Limitations

The clinical research base is concentrated on defined, short timeframes, with follow-up durations often being limited to a maximum of one to two weeks. This short-term focus indicates that long-term effects are not fully established, and there is limited information for outcomes related to the durability of effect or maintenance of relief.

Studies primarily focused on otherwise healthy adults experiencing acute episodes. Data for certain groups, such as pediatric patients, remain insufficient, and the available evidence is not extensive for those with significant comorbidities. Comparative evidence is also lacking in some areas against all the newer options available on the market. Furthermore, research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dexketoprofeno Qualigen (FAQ)

Q: What kind of pain is Dexketoprofeno Qualigen typically used for?

A: According to the official product information, this medicine is indicated for the short-term management of pain that is classified as mild to moderate in intensity. This typically includes discomfort from issues such as muscle or joint pain, menstrual pain (dysmenorrhoea), or toothache.


Q: Does Dexketoprofeno Qualigen help with headaches?

A: Official product information sometimes lists its use for headache as one of the types of mild to moderate pain for which it is indicated. Its general classification is for pain and inflammation in acute situations.


Q: How quickly does Dexketoprofeno Qualigen usually start working?

A: Official studies indicate that this medicine has a rapid absorption rate. Following oral use, the onset of action is generally described as being within 30 minutes, with the highest concentration of the active substance often achieved within a short time after administration.


Q: What is the expected duration of effect after taking Dexketoprofeno Qualigen?

A: Regulatory documents describe the active substance as having a plasma half-life of approximately 4 to 6 hours. The pain-relieving effect has been observed to be sustained for a period related to this half-life.


Q: Is it common to feel stomach discomfort after taking this medicine?

A: Yes, regulatory documents list gastrointestinal side effects as the most frequently reported. Indigestion (dyspepsia), nausea, vomiting, and general tummy (abdominal) discomfort are classified as Common, meaning they may affect up to 10 out of every 100 users.


Q: What are the most commonly reported side effects of Dexketoprofeno Qualigen?

A: The side effects classified as Common are those most frequently reported in official documentation, affecting up to 1 in 10 users. These generally include nausea and/or vomiting, abdominal pain, and diarrhoea or digestive problems (dyspepsia).


Q: Does Dexketoprofeno Qualigen cause drowsiness?

A: Official labeling lists some effects on the nervous system as Uncommon side effects, which may affect up to 1 in 100 users. These include dizziness (vertigo), drowsiness (somnolence), and sleep disturbances.


Q: Is it possible for Dexketoprofeno Qualigen to affect blood pressure?

A: The official product information states that elevated blood pressure (hypertension) is an Uncommon side effect, meaning it may affect up to 1 in 100 users. Changes in blood pressure are a documented risk with NSAID use.


Q: Is Dexketoprofeno Qualigen suitable for older adults?

A: Older adults may use this medicine, but they are noted in official guidelines as having an increased vulnerability to adverse effects. Due to these documented risks, treatment must be started at the lowest available daily dose, and official guidelines note that patient monitoring is indicated.


Q: Why is Dexketoprofeno Qualigen described as a short-term treatment?

A: Official documentation emphasizes short-term use because the documented risk of certain serious side effects, particularly those affecting the stomach, heart, and blood vessels, may be increased with high doses and prolonged duration of treatment.


Q: Can Dexketoprofeno Qualigen be used to manage fever?

A: Although the official indications typically focus on pain and inflammation, the drug's mechanism of action is described in the product information as reversing the fever-inducing signal in the brain. This action is consistent with a documented antipyretic (fever-reducing) action.


Q: Is Dexketoprofeno Qualigen linked to any gastrointestinal side effects?

A: Yes, gastrointestinal problems are the most frequently reported group of side effects. This includes common issues like nausea and diarrhoea, as well as the rare, documented risks of serious events like ulceration, haemorrhage, or perforation.


Q: How is Dexketoprofeno Qualigen generally eliminated from the body?

A: According to pharmacokinetic data, the drug is primarily eliminated from the body through metabolism in the liver. After this process, the substance is then primarily excreted via the kidneys (in the urine) after being converted into a water-soluble form.


Q: What are the official warnings about allergic reactions to Dexketoprofeno Qualigen?

A: The official documentation states that treatment cessation and immediate medical assistance are required if signs of a serious allergic reaction occur. These documented signs include swelling of the face or mouth, severe dizziness, or difficulty breathing.


Q: Is it true that this drug can affect liver function?

A: Official documents state that severe hepatic (liver) impairment is an absolute contraindication, meaning the drug should not be used in this situation. Abnormal liver function tests are also listed as an Uncommon side effect in the official safety profile.


Q: Are there warnings about driving or operating machinery while using this medicine?

A: Yes, official warnings state that since this medicine can cause side effects like dizziness, drowsiness, and blurred vision, official warnings state that activities requiring alertness, such as driving or operating machinery, may be impaired due to these effects.


Q: Is it common for Dexketoprofeno Qualigen to cause nausea?

A: Yes, nausea is listed as a Common side effect in regulatory documents, meaning it is frequently observed and may affect between 1 and 10 users in 100.


Q: Can Dexketoprofeno Qualigen interact with medication for diabetes?

A: Yes, official documents advise that this medicine may increase the blood glucose-lowering effect of sulfonylureas (medications used to manage diabetes). Official guidance notes that a review of blood glucose levels is indicated when these medications are used together.


Q: Does this drug have a risk of dependence?

A: The medicine is classified as a Non-steroidal Anti-inflammatory Drug (NSAID) and a non-opioid analgesic. These classes of medications are not associated with a risk of physical dependence.


Q: Are there known drug interactions with psychiatric medications?

A: The official interaction profile mentions that Selective Serotonin Reuptake Inhibitors (SSRIs), a type of psychiatric medication, should be used with caution. This is due to the documented increased risk of gastrointestinal bleeding when co-administered with this drug.


Q: What is the half-life of Dexketoprofeno described as?

A: According to pharmacokinetic data, the active substance has a plasma half-life (the time it takes for the concentration to halve in the blood) of approximately 4 to 6 hours after oral ingestion.


Q: What happens if Dexketoprofeno Qualigen is taken close to the time of another medicine?

A: The potential for one drug to affect the level or action of another is determined by the specific agents involved. Regulatory information advises that co-administration should be determined based on the documented interaction profile of each specific drug, as listed in the official documents.


Q: Are there different strengths of Dexketoprofeno Qualigen available?

A: Yes, the product is available in different strengths for its approved administration routes. This commonly includes a 25 mg tablet for oral use and a 50 mg/2 ml solution for injectable administration, as noted in the product's composition details.


Q: Can Dexketoprofeno Qualigen be taken on an empty stomach?

A: Oral forms are generally recommended in official guidelines to be taken on an empty stomach, specifically at least 15 to 30 minutes before meals. This is intended to achieve the fastest and most efficient absorption rate.


Q: Is it described as safe to drink alcohol while using Dexketoprofeno Qualigen?

A: Official documentation states that the consumption of alcohol is not recommended. This is due to an officially documented increased risk of serious gastrointestinal side effects when alcohol is consumed while using this medicine.


Q: Are there any foods or drinks mentioned in official sources that should be avoided with this drug?

A: Official guidelines recommend taking the medicine separated from food to ensure quick absorption. Alcohol is the only specific drink mentioned in the interaction profile that is not recommended due to an increased risk of side effects.

Advertisements

How should Dexketoprofeno Qualigen be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions:

Regulatory documents stipulate that Dexketoprofeno Qualigen tablets or granules should generally be stored at ambient conditions, typically not exceeding 30 C. The medicine must be kept in its original packaging (blister or sachet) to ensure its stability and protect it from environmental factors until the end of its stated shelf-life. This medicinal product must always be kept out of the sight and reach of children.

Disposal Instructions:

Expired or unused medicine must not be disposed of via household waste, standard garbage, or wastewater, as this can pose risks to the environment. Official regulatory guidelines require the medicine to be returned to a designated pharmacy collection point (such as a take-back program) for proper, environmentally safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexketoprofeno Qualigen found in:

A-Z Index: